Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

B-specific

Financiado

Cerrado

B-specific: B-cell related gene and protein markers with prognostic and therapeu...

B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVD Atherosclerosis is the major underlying condition of cardiovascular disease (CVD) and one the leading causes of mortality. Rupture or erosion of atherosclerotic lesions can lead to acute cardiovascular events, such as myocardial i... ver más

30/09/2027

ULEI

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-01

HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-01: EIC Pathfinder Challenge: Carbon di... Scope:Climate change, global warming and water/soil pollution are unprecedented challenges for the p...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

ULEI

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CARDIOMICS Cardiomics Use of omics methods in large populations for i... 1M€ Cerrado

RYC-2009-04599 Análisis metabonómico de la expresión diferencial de miRNA e... 192K€ Cerrado

The B-MIracle The function of B cells in myocardial infarction-accelerated... 1M€ Cerrado

TargetMI A Multi-Omics Approach for Novel Drug Targets, Biomarkers an... 4M€ Cerrado

COMBI-BIO Development of COMBInatorial BIOmarkers for subclinical athe... 4M€ Cerrado

RISKYCAD Personalized diagnostics and treatment of high risk coronary... 8M€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2023-10-01
Fecha Fin: 2027-09-30

Líder del proyecto

UNIVERSITEIT LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Atherosclerosis is the major underlying condition of cardiovascular disease (CVD) and one the leading causes of mortality. Rupture or erosion of atherosclerotic lesions can lead to acute cardiovascular events, such as myocardial infarction and stroke, making biomarkers to diagnose patients at risk for these events and develop tailored preventive interventions, an urgent need. Although atherosclerosis is a chronic inflammatory disease, clinical investigation of the adaptive immune system as a potential rheostat for disease development has been limited. The B-specific consortium aims to classify and mitigate risk of CVD by generating novel types of genetic data and defining novel prognostic and therapeutic targets attained from our recent discovery of a specific B-cell subset. We will employ state-of-the-art technology, including single cell RNA sequencing, BCR repertoire analysis and mass spectrometry-based identification of autoantigens in CVD patient material. With access to large population-based cohorts (FIMCOD, ERGO Study) spanning healthy adults of 40-105 years of age, we aim to assess the prognostic value of circulating B cell subsets and antibodies in (sub)clinical atherosclerosis and investigate the contribution of genetic disposition. Using the extensive genomics data of the ERGO Study, we will be able to determine causal links between the prognostic indicators and disease progression by applying Mendelian Randomization experiments and confirm these relationships in ex vivo and in vivo models of atherosclerosis. Based on these findings, B-specific aims to develop at least 1 proof-of-concept therapy targeting specific B cells. B-specific will implement an active open science platform and in combination with a targeted dissemination approach to healthcare professionals, we aim to impact cardiology practice and provide important new means of patient stratification and treatment options.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores